European Journal of Neurology最新文献

{"title":"Impact of elevated lipoprotein(a) levels on the functional outcomes of ischemic stroke patients: A systematic review and meta-analysis","authors":"Huarong Liu,&nbsp;Bo Li,&nbsp;Ting Lu,&nbsp;Chong Chen,&nbsp;Xi Xiong,&nbsp;Xing Li,&nbsp;Rengui Yang","doi":"10.1111/ene.16501","DOIUrl":"10.1111/ene.16501","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and purpose</h3>\u0000 \u0000 <p>Elevated serum lipoprotein(a) (Lp[a]) levels have been linked to an increased incidence of stroke. This systematic review and meta-analysis aimed to evaluate the impact of serum Lp(a) on the functional outcomes of patients with ischemic stroke (IS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a comprehensive search of the MEDLINE, Web of Science, Embase, Wanfang, and China National Knowledge Infrastructure databases to identify relevant cohort studies. A random effects model was utilized to synthesize the data, accounting for study heterogeneity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The analysis included 11 cohort studies comprising 11,958 patients with IS. Pooled results indicated that high baseline Lp(a) levels were associated with an increased risk of poor functional outcomes during follow-up (odds ratio [OR] = 2.13, 95% confidence interval = 1.67–2.71, <i>p</i> &lt; 0.001, <i>I</i>² = 62%). Subgroup analyses revealed that the relationship between high Lp(a) levels and the risk of poor functional outcomes was more pronounced at discharge (OR = 3.25), 3 months (OR = 2.02), and 6 months (OR = 2.11) poststroke, compared to 12 months (OR = 1.25, <i>p</i> for subgroup difference &lt; 0.001). Furthermore, the association was attenuated yet remained significant in studies adjusting for low-density lipoprotein cholesterol (LDL-C) compared to those that did not adjust for LDL-C (OR = 1.69 vs. 2.63, <i>p</i> for subgroup difference = 0.03).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>High serum Lp(a) levels at baseline are significantly associated with poor functional outcomes in patients with IS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of expiratory muscle strength training on voluntary cough effectiveness in Huntington's disease","authors":"Romana Konvalinkova,&nbsp;Martin Srp,&nbsp;Kristyna Doleckova,&nbsp;Vaclav Capek,&nbsp;Ota Gal,&nbsp;Martina Hoskovcova,&nbsp;Radim Kliment,&nbsp;Jan Muzik,&nbsp;Evzen Ruzicka,&nbsp;Jiri Klempir","doi":"10.1111/ene.16500","DOIUrl":"10.1111/ene.16500","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and purpose</h3>\u0000 \u0000 <p>Dysfunction of the airway defence system in Huntington's disease (HD) is a significant but often overlooked problem. Although expiratory muscle strength training (EMST) is frequently utilized in cough effectiveness treatment, its specific impact in HD patients has not yet been explored. This study investigated the effects of EMST on voluntary peak cough flow (vPCF) in HD patients and evaluated the retention of potential gains post-intervention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective case-controlled trial, 29 HD patients completed an 8-week wait-to-start period, which served to identify the natural development of expiratory muscle strength and vPCF. This was followed by 8 weeks of EMST training and an additional 8 weeks of follow-up. The study's outcome parameters, vPCF and maximum expiratory pressure (MEP), were measured against those of age- and sex-matched healthy controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Huntington's disease patients had significantly lower MEP (<i>p</i> &lt; 0.001) and vPCF (<i>p</i> = 0.012) compared to healthy controls at baseline. Following the EMST, significant improvements in MEP (<i>d</i> = 1.39, <i>p</i> &lt; 0.001) and vPCF (<i>d</i> = 0.77, <i>p</i> = 0.001) were observed, with HD patients reaching the cough performance levels of healthy subjects. However, these gains diminished during the follow-up, with a significant decline in vPCF (<i>d</i> = −0.451, <i>p</i> = 0.03) and in MEP (<i>d</i> = −0.71; <i>p</i> = 0.002).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Expiratory muscle strength training improves expiratory muscle strength and voluntary cough effectiveness in HD patients, but an ongoing maintenance programme is necessary to sustain the improvements.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved comprehension of influenza-related headaches: Perspectives and suggestions for incidence and prevalence of headache in influenza—Response","authors":"David García-Azorín,&nbsp;Laura Santana-López,&nbsp;Ana Ordax-Díez,&nbsp;José Eugenio Lozano-Alonso,&nbsp;Diego Macias Saint-Gerons,&nbsp;Yésica González-Osorio,&nbsp;Silvia Rojo-Rello,&nbsp;José M. Eiros,&nbsp;Javier Sánchez-Martínez,&nbsp;Álvaro Sierra-Mencía,&nbsp;Andrea Recio-García,&nbsp;Ángel Luis Guerrero-Peral,&nbsp;Ivan Sanz-Muñoz","doi":"10.1111/ene.16478","DOIUrl":"10.1111/ene.16478","url":null,"abstract":"&lt;p&gt;One of the strengths of this study was the systematic and consistent evaluation of a series of symptoms when patients seek medical attention at primary care [&lt;span&gt;1&lt;/span&gt;]. This was done through a clinical in-person interview by a trained healthcare provider. Since headache was one of the evaluated symptoms, its incidence and prevalence could be assessed.&lt;/p&gt;&lt;p&gt;Khan et al. provided a series of suggestions that we acknowledge and would like to comment on [&lt;span&gt;2&lt;/span&gt;]. In our understanding, the use of medication could have influenced the prevalence of headaches in the following ways: (a) symptomatic treatment could have decreased the duration of the headache, and by the time patients were evaluated in primary care the headache might not be present; (b) headaches could have started after the medical evaluation [&lt;span&gt;1&lt;/span&gt;]. However, according to other studies, headaches seem to be an early symptom that typically resolves within 4 days [&lt;span&gt;3&lt;/span&gt;]. If so, the true prevalence of headaches could be underestimated. Regarding the use of antiviral therapies, these require a medical prescription, so it is not possible that these could have modified the prevalence of headaches. It would be interesting for future studies to evaluate whether these therapies may modify the clinical phenotype and/or duration of headaches.&lt;/p&gt;&lt;p&gt;Regarding the role of epidemiological contacts and travel history, as an epidemic disorder it is common that the number of cases peaks during certain periods of the year when the transmission of the virus is higher within the population [&lt;span&gt;1&lt;/span&gt;]. According to the literature, the main factors that seem to influence the virulence are the specific circulating strains and variants and the proportion of vaccinated individuals [&lt;span&gt;4&lt;/span&gt;]. With more than 8000 studied patients and 12 influenza seasons, the picture seems comprehensive enough to evaluate possible annual differences, which did not seem to be that remarkable regarding headache epidemiology [&lt;span&gt;1&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Concerning the probability of seeking medical attention, we believe that Khan et al. [&lt;span&gt;2&lt;/span&gt;] refer to another publication from the same study [&lt;span&gt;5&lt;/span&gt;]. In that study, as Khan et al. [&lt;span&gt;2&lt;/span&gt;] point out, we did not prospectively follow up with patients, and we were only able to compare whether patients with headaches were referred to hospitals more or less frequently. It was observed that patients with headaches had 54% lower odds of being referred to the hospital, and it seemed clear that this was not observed by chance [&lt;span&gt;5&lt;/span&gt;]. The reasons are not known with certainty. However, we hypothesize that the reason may be a more efficient immune response. Patients with headaches also had a higher frequency of other symptoms commonly associated with the immune response and the release of cytokines and interleukins. This has been observed with other acute viral infections, and we aim to validate it in future studies [","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pelvic autonomic dysfunction is common in patients with pure autonomic failure","authors":"E. Vichayanrat,&nbsp;C. Hentzen,&nbsp;S. Simeoni,&nbsp;M. Pakzad,&nbsp;V. Iodice,&nbsp;Jalesh N. Panicker","doi":"10.1111/ene.16486","DOIUrl":"10.1111/ene.16486","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Purpose</h3>\u0000 \u0000 <p>Pure autonomic failure (PAF) presents primarily as cardiovascular autonomic failure and may phenoconvert to other neurodegenerative disorders. However, the involvement of other autonomic functions has been poorly evaluated. This study aims to characterize genitourinary and bowel dysfunction and explore their relationship with cardiovascular autonomic dysfunction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Pure autonomic failure patients underwent cardiovascular autonomic testing and an assessment of pelvic autonomic dysfunction using urinary, sexual symptoms questionnaires and a bladder diary. Demographic, clinical features and related medical comorbidities were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-five patients (10 males) with PAF were included (mean age 71 ± 8 years; disease duration 13 ± 8 years). 96% (24/25) reported lower urinary tract symptoms, of which overactive bladder symptoms were most commonly reported (<i>n</i> = 23; 92%; median overactive subscore 8, interquartile range [IQR] 3–11), followed by voiding difficulties (<i>n</i> = 19; 76%; median low stream subscore 2, IQR 1–3) using the Urinary Symptom Profile; however, only four (16%) required clean intermittent self-catheterization. Sexual dysfunction was common (<i>n</i> = 21; 84%) using the Arizona Sexual Experience Scale. Mild faecal incontinence and constipation were reported. 86% (19/22) had nocturnal polyuria (NP) and the median NP index was 47% (IQR 38%–51%; normal range &lt;33%). 77% (10/13) had voiding dysfunction and 31% (4/13) had post-void residual urine &gt;100 mL. There were no significant correlations between the need for catheterization and the degree of NP with age, disease duration and cardiovascular autonomic parameters (<i>p</i> &gt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Nocturnal polyuria, genitourinary and bowel symptoms are commonly seen in PAF. The pathophysiology of NP in PAF is most likely multifactorial and may occur independent of cardiovascular autonomic failure.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conclusion","authors":"Paul Boon,&nbsp;Elena Moro","doi":"10.1111/ene.16474","DOIUrl":"10.1111/ene.16474","url":null,"abstract":"&lt;p&gt;We hope that the readers of this &lt;i&gt;European Journal of Neurology&lt;/i&gt; Special Issue have enjoyed the lively descriptions of the amazing journey in the past 10 years that our discipline, neurology, has achieved thanks to the extraordinary contribution of neurologists, neurological associations, and people with neurological diseases. In this context, we are also particularly proud to highlight the remarkable developments and achievements of the European Academy of Neurology (EAN), which celebrates its 10-year anniversary in 2024. The experience gained within the former European Federation of Neurological Societies (EFNS) and the European Neurological Society (ENS) has allowed the EAN to immediately start fulfilling its main mission and vision – to reduce the burden of neurological disorders and to provide a home of neurology – with many successful initiatives. The collegial and hard work of the members of the consecutive EAN Boards, the Head Office, the Scientific Panels, and the Committees has contributed to consolidate a society that now includes and represents 48 vibrant National Neurological Societies in Europe. EAN has exponentially grown within these 10 years in terms of increasing the number of members, particularly young neurologists, growing the number and quality of scientific and educational activities, increasing the number and strengthening of national and international partnerships, increasing overall quality standards, and increasing involvement at the European Union (EU) level in Brussels. During the COVID-19 pandemic, EAN has continued to help and serve the neurological community with several initiatives, including setting up a large European patient registry. In the past 10 years, the EAN Annual Congress has become one of the best attended and impactful neurological meetings for general neurologists and subspecialty neurologists alike. EAN is increasingly recognized as the European general neurology organization with a global reach. EAN is now at the forefront of global brain awareness and advocacy efforts.&lt;/p&gt;&lt;p&gt;The EAN has published a comprehensive Neurological Research Agenda for Europe, a patient-centered research strategy that was particularly missing for clinical neurology. EAN has also started a Brain Health Strategy, the Brain Health Mission (BHM), and a Strategic Brain Health Road Map involving patient representatives and patient organizations, the EAN Scientific Panels, the National Neurological Societies, a number of closely affiliated scientific societies, and a large number of other stakeholders and EU partners.&lt;/p&gt;&lt;p&gt;There are several other leading EAN actions and proposals in the pipeline. In these difficult, belligerent and divergent times, EAN wants to recognize diversity, inclusion, and equity as essential determinants when dealing with neurological diseases. To adequately address the exponential growth in knowledge and technology development, and the constant and rapid changes in environment and climate, and ","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 11","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved diagnostic performance of high-sensitivity cardiac troponins in muscle dystrophies using comprehensive definition criteria for cardiac involvement: A longitudinal study on 35 patients","authors":"Mustafa Yildirim,&nbsp;Christian Salbach,&nbsp;Christoph Reich,&nbsp;Regina Pribe-Wolferts,&nbsp;Barbara Ruth Milles,&nbsp;Tobias Täger,&nbsp;Matthias Mueller-Hennessen,&nbsp;Markus Weiler,&nbsp;Benjamin Meder,&nbsp;Norbert Frey,&nbsp;Evangelos Giannitsis","doi":"10.1111/ene.16498","DOIUrl":"10.1111/ene.16498","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and purpose</h3>\u0000 \u0000 <p>Sparse information is available on the correct interpretation of elevated high-sensitivity cardiac troponin (hs-cTn) in confirmed muscular dystrophies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Serum concentrations of hs-cTn T (hs-cTnT) and hs-cTn I (hs-cTnI) were determined in 35 stable outpatients with confirmed skeletal muscle dystrophies. We calculated sensitivities, specificities, and positive and negative predictive values of hs-cTnT and hs-cTnI for identification of cardiac involvement using a comprehensive definition that included diastolic left ventricular and right ventricular function, strain analysis using two-dimensional transthoracic echocardiogram and magnetic resonance imaging, myocardial biopsies, and consideration of a variety of triggers for cardiac injury, including arrhythmias, conduction disorders, and hypoxemia due to respiratory failure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Cardiac involvement was diagnosed in 34 of 35 cases. Specificities of hs-cTnT increased from 12.5% to 100% (<i>p</i> = 0.0006) applying the comprehensive definition compared to a definition based on electrocardiography and echocardiography alone. At the recommended 99th percentile upper limit of normal, sensitivities were significantly lower for hs-cTnI than for hs-cTnT (29.4% vs. 100%, <i>p</i> = 0.0164). Conversely, the specificities of hs-cTnT and hs-cTnI increased to 100% when using the comprehensive definition criteria for diagnosing cardiac involvement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Elevated hs-cTnT but not hs-cTnI discriminates cardiac involvement in cases with confirmed skeletal muscle dystrophies with very high sensitivity and 100% specificity. Prior reports on worse performance may be explained by the use of less sensitive imaging methods or incomplete assessment of cardiac involvement.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urodynamic study and its correlation with cardiac meta-iodobenzylguanidine (MIBG) in body-first and brain-first subtypes of Parkinson's disease","authors":"Min Seung Kim,&nbsp;Jong Keun Kim,&nbsp;In Hee Kwak,&nbsp;Jeongjae Lee,&nbsp;Young Eun Kim,&nbsp;Hyeo-Il Ma,&nbsp;Suk Yun Kang","doi":"10.1111/ene.16497","DOIUrl":"10.1111/ene.16497","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and purpose</h3>\u0000 \u0000 <p>Lower urinary tract symptoms (LUTS) are frequently observed in patients with Parkinson's disease (PD), but the underlying mechanism remains elusive. The concept of “body-first” and “brain-first” subtypes in PD has been proposed, but the correlation of PD subtype with LUTS remains unclear. We aimed to investigate the disparities in urological dysfunctions between body-first and brain-first subtypes of PD using urodynamic studies (UDS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We reviewed patients with PD (disease duration &lt;3 years) who had undergone UDS and completed urological questionnaires (Overactive Bladder Symptom Score [OABSS] and International Prostate Symptom Score [IPSS]) and a voiding diary. Patients were categorized as having body-first or brain-first PD based on cardiac sympathetic denervation (CSD) using cardiac meta-iodobenzylguanidine (MIBG) uptake and the presence of rapid eye movement sleep behavior disorder (RBD), assessed using a questionnaire (PD with CSD and RBD indicating the body-first subtype).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 55 patients with PD were categorized into body-first PD (<i>n</i> = 37) and brain-first PD (<i>n</i> = 18) groups. The body-first PD group exhibited smaller voiding volume and first desire volume (FDV) than the brain-first PD group (<i>p</i> &lt; 0.05 in both). Also, the body-first PD group had higher OABSS and IPSS scores, and higher prevalence of overactive bladder diagnosed by OABSS, compared to the brain-first PD group. In multiple linear regression, cardiac MIBG uptake was positively correlated with FDV and voiding volume and negatively correlated with OABSS and IPSS (<i>p</i> &lt; 0.05 in all).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with the body-first PD subtype exhibited more pronounced overactive bladder symptoms and impaired storage function in the early stage of disease. Additionally, cardiac MIBG was significantly associated with urological dysfunction.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between migraine and epilepsy in a large population-based cohort: The HUNT Study","authors":"Helene Engstrand,&nbsp;Eline Revdal,&nbsp;Maria Bengtson Argren,&nbsp;Knut Hagen,&nbsp;John-Anker Zwart,&nbsp;Eylert Brodtkorb,&nbsp;Bendik Slagsvold Winsvold","doi":"10.1111/ene.16496","DOIUrl":"10.1111/ene.16496","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Purpose</h3>\u0000 \u0000 <p>Several studies have reported substantial comorbidity between epilepsy and migraine. Most of these were based on clinical cohorts or used unvalidated diagnostic instruments. Our study re-examined this association in a large general population cohort using validated diagnoses for both disorders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 65,407 participants (≥20 years old) from HUNT (the Trøndelag Health Study) were classified for migraine and nonmigraine headache using a validated questionnaire. Medical record review was used to validate and classify epilepsy in 364 participants (cases), who were compared with 63,298 participants without epilepsy (controls). The association between epilepsy and migraine was analysed using logistic regression adjusted for sex and age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients with epilepsy had no increased prevalence of migraine (odds ratio [OR] = 0.95, 95% confidence interval [CI] = 0.68–1.33) or nonmigraine headache (OR = 1.18, 95% CI = 0.93–1.50) compared to controls. When stratified by headache frequency, epilepsy was associated with a higher prevalence of migraine with highly frequent headache (≥7 days/month; OR = 1.73, 95% CI = 1.08–2.78).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Migraine was equally common in people with and without epilepsy. Patients with epilepsy who suffered from migraine were more prone to having highly frequent migraine.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of dementia with impaired kidney function and plasma biomarkers: A population-based study","authors":"Nan Wang,&nbsp;Yixun Ma,&nbsp;Xiaoyan Liang,&nbsp;Wenxin Fa,&nbsp;Xunyao Tian,&nbsp;Cuicui Liu,&nbsp;Min Zhu,&nbsp;Na Tian,&nbsp;Keke Liu,&nbsp;Shi Tang,&nbsp;Lin Song,&nbsp;Lin Cong,&nbsp;Lu Dai,&nbsp;Hong Xu,&nbsp;Yongxiang Wang,&nbsp;Tingting Hou,&nbsp;Yifeng Du,&nbsp;Chengxuan Qiu","doi":"10.1111/ene.16488","DOIUrl":"10.1111/ene.16488","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Purpose</h3>\u0000 \u0000 <p>Emerging evidence has linked impaired kidney function with dementia in older adults, but the neuropathological pathways underlying their association remain poorly understood. We sought to examine the relationships of kidney function with dementia and plasma biomarkers in a Chinese rural population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This population-based study used data from the baseline examination of the Multimodal Interventions to Delay Dementia and Disability in rural China (MIND-China) cohort (March–September 2018; <i>n</i> = 5715). Kidney function was assessed using estimated glomerular filtration rate (eGFR) based on serum creatinine level. Dementia, Alzheimer's disease (AD) and vascular dementia (VaD) were diagnosed according to the international criteria. Plasma biomarkers were measured using the SIMOA platform in a subsample (<i>n</i> = 1446). Data were analyzed using logistic, general linear, and mediation models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 5715 participants, 306 were diagnosed with dementia, including 195 with AD and 100 with VaD. Impaired kidney function (eGFR &lt;60 vs. ≥90 mL/min/1.73 m²) was associated with multivariable-adjusted odds ratios of 2.24 (95% confidence interval [CI] 1.44–3.46) for all-cause dementia, 1.85 (1.07–3.18) for AD, and 2.49 (1.16–5.22) for VaD. In the biomarker subsample, impaired kidney function was significantly associated with higher plasma amyloid-β (Aβ)40 (<i>β</i>-coefficient = 54.36, 95% CI 43.34–65.39), Aβ42 (<i>β</i>-coefficient = 3.14, 95% CI 2.42–3.86), neurofilament light chain (<i>β</i>-coefficient = 10.62, 95% CI 5.62–15.62), and total tau (<i>β</i>-coefficient = 0.68, 95% CI 0.44–0.91), and a lower Aβ42/Aβ40 ratio (<i>β</i>-coefficient = −4.11, 95% CI −8.08 to −0.14). The mediation analysis showed that plasma total tau significantly mediated 21.76% of the association between impaired kidney function and AD (<i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Impaired kidney function is associated with dementia and plasma biomarkers among rural-dwelling older Chinese adults, and the association with AD is partly mediated by plasma biomarkers for neurodegeneration.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated serum circulating cell-free mitochondrial DNA in amyotrophic lateral sclerosis","authors":"Jieyu Li,&nbsp;Chao Gao,&nbsp;Qingqing Wang,&nbsp;Jing Liu,&nbsp;Zhiying Xie,&nbsp;Yawen Zhao,&nbsp;Meng Yu,&nbsp;Yiming Zheng,&nbsp;He Lv,&nbsp;Wei Zhang,&nbsp;Yun Yuan,&nbsp;Lingchao Meng,&nbsp;Jianwen Deng,&nbsp;Zhaoxia Wang","doi":"10.1111/ene.16493","DOIUrl":"10.1111/ene.16493","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Purpose</h3>\u0000 \u0000 <p>The substantial role of inflammation in amyotrophic lateral sclerosis (ALS) is gaining support from recent research. Studies indicate that circulating cell-free mitochondrial DNA (ccf-mtDNA) can activate the immune system and is associated with neurodegenerative diseases. This research was designed to quantify ccf-mtDNA levels in the serum of ALS patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The medical records of ALS patients were reviewed. Serum ccf-mtDNA levels of patients with ALS (<i>n</i> = 62) and age-matched healthy controls (<i>n</i> = 46) were measured and compared. Additionally, serum interleukin-6 (IL-6) levels were measured using an enzyme-linked immunosorbent assay in 26 ALS patients. Correlations between variables were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Serum ccf-mtDNA was notably higher in the patients with ALS. When stratified by genotype, the superoxide dismutase 1 (<i>SOD1</i>) mutation group showed the greatest increase in ccf-mtDNA levels relative to other ALS patients. Among all 108 individuals, a cut-off set at 1.1 × 10⁵ mtDNA copies on a receiver-operating characteristic curve identified patients with ALS with 80.7% sensitivity and 50.0% specificity; the area under the curve was 0.69 (<i>p</i> &lt; 0.001). Furthermore, serum ccf-mtDNA levels correlated negatively with the progression rate of ALS (ΔFS; <i>rs</i> = −0.26, <i>p</i> = 0.044), but not the ALSFRS-R score (<i>rs</i> = 0.06, <i>p</i> = 0.625). Importantly, the correlation between ccf-mtDNA and ΔFS was more pronounced in the <i>SOD1</i> mutation group (<i>rs</i> = −0.62, <i>p</i> = 0.018). Lastly, a significant positive association was observed between serum ccf-mtDNA levels and IL-6 levels in ALS (<i>r</i> s= 0.41, <i>p</i> = 0.038).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study found increased serum ccf-mtDNA in ALS patients, suggesting a link to inflammatory processes and disease mechanism. Moreover, ccf-mtDNA could be an indicator for ALS progression, especially in those with the <i>SOD1</i> mutation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}